Julie & Holleman is investigating the proposed acquisition of Personalis, Inc. by Tempus AI, Inc. Tempus was already a Personalis stockholder and commercial partner before agreeing to acquire the shares of Personalis it does not already own. Because Tempus was not an unrelated third-party bidder, the transaction presents potential conflicts of interest, and the firm is examining whether the process leading to the transaction and its terms are fair to Personalis's public stockholders.
What happened
On July 20, 2026, Personalis entered into a merger agreement to be acquired by Tempus AI, Inc. The agreement values Personalis at $16.25 per share, which the companies describe as representing an enterprise value of approximately $1.5 billion, net of Tempus's existing ownership interest in Personalis. If the transaction closes, Personalis will become part of Tempus and its public stockholders will no longer hold shares in an independent Personalis.
The consideration is payable in Tempus common stock through a floating exchange ratio, with Tempus having the option to pay up to 50% of the consideration in cash. According to the filings, Personalis's board of directors unanimously approved the merger agreement and resolved to recommend that stockholders adopt it. The companies expect the transaction to close in late 2026 or early 2027, subject to approval by Personalis stockholders, applicable regulatory approvals, and other customary closing conditions.
Why we're looking at it
Tempus was not an unrelated third-party bidder. Before agreeing to acquire Personalis, Tempus already held an ownership interest in the company — approximately 12% of its stock — and was an established commercial partner. That commercial relationship dates to November 2023, when the companies entered a strategic collaboration under which Tempus commercializes Personalis's NeXT Personal molecular residual disease (MRD) test.
A buyer that already owns a stake in, and has a strategic and commercial relationship with, the company it is acquiring may occupy a different position from the company's public stockholders. We are examining the circumstances surrounding the proposed transaction, including the process that led to the agreement with Tempus, the potential conflicts arising from Tempus's preexisting ownership and relationship with Personalis, and whether the transaction treats Personalis's public stockholders fairly.
What we're investigating
We are investigating whether Personalis's directors, officers, and others involved in the transaction fulfilled their fiduciary and other legal obligations to the company's public stockholders. We are examining, among other things:
- the process leading to the transaction, including how it was negotiated and approved;
- potential conflicts arising from Tempus's preexisting ownership interest in Personalis and its strategic and commercial relationship with the company;
- whether stockholders will receive all material information needed to evaluate the transaction; and
- whether the transaction is fair to Personalis's public stockholders.